Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: Continued experience of a phase I trial in rectal cancer patients

被引：335

作者：

Willett, CG ^{[1
]}

Boucher, Y

Duda, DG

di Tomaso, E

Munn, LL

Tong, RT

Kozin, SV

Petit, L

Jain, RK

Chung, DC

Sahani, DV

Kalva, SP

Cohen, KS

Scadden, DT

Fischman, AJ

Clark, JW

Ryan, DP

Zhu, AX

Blaszkowsky, LS

Shellito, PC

Mino-Kenudson, M

Lauwers, GY

机构：

[1] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA

[2] Harvard Univ, Sch Med, Boston, MA 02115 USA

[3] Massachusetts Gen Hosp, Gastrointestinal Unit, Dept Med, Boston, MA 02114 USA

[4] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA

[5] Harvard Univ, Ctr Regenerat Med, Sch Med, Massachusetts Gen Hosp, Boston, MA 02115 USA

[6] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA

[7] Massachusetts Gen Hosp, Dept Nucl Med, Boston, MA 02114 USA

[8] Massachusetts Gen Hosp, Div Hematol Oncol, Boston, MA 02114 USA

[9] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA

[10] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 31期

关键词：

D O I：

10.1200/JCO.2005.02.5635

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：8136 / 8139

页数：4

共 17 条

[1]

*AM JOINT COMM CAN, 2002, COL RECT, P121

[2]

Ellis Lee M, 2005, Nat Rev Drug Discov, VSuppl, pS8

[3] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer [J].

Hurwitz, H ;

Fehrenbacher, L ;

Novotny, W ;

Cartwright, T ;

Hainsworth, J ;

Heim, W ;

Berlin, J ;

Baron, A ;

Griffing, S ;

Holmgren, E ;

Ferrara, N ;

Fyfe, G ;

Rogers, B ;

Ross, R ;

Kabbinavar, F .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23) :2335-2342

[4] Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy [J].

Jain, RK .

NATURE MEDICINE, 2001, 7 (09) :987-989

[5] Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy [J].

Jain, RK .

SCIENCE, 2005, 307 (5706) :58-62

[6] Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer [J].

Johnson, DH ;

Fehrenbacher, L ;

Novotny, WF ;

Herbst, RS ;

Nemunaitis, JJ ;

Jablons, DM ;

Langer, CJ ;

DeVore, RF ;

Gaudreault, J ;

Damico, LA ;

Holmgren, E ;

Kabbinavar, F .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (11) :2184-2191

[7] Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer [J].

Kabbinavar, F ;

Hurwitz, HI ;

Fehrenbacher, L ;

Meropol, NJ ;

Novotny, WF ;

Lieberman, G ;

Griffing, S ;

Bergsland, E .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) :60-65

[8]

Lee CG, 2000, CANCER RES, V60, P5565

[9] Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis [J].

Maisonpierre, PC ;

Suri, C ;

Jones, PF ;

Bartunkova, S ;

Wiegand, S ;

Radziejewski, C ;

Compton, D ;

McClain, J ;

Aldrich, TH ;

Papadopoulos, N ;

Daly, TJ ;

Davis, S ;

Sato, TN ;

Yancopoulos, GD .

SCIENCE, 1997, 277 (5322) :55-60

[10] In vivo radioprotective effects of angiogenic growth factors on the small bowel of C3H mice [J].

Okunieff, P ;

Mester, M ;

Wang, J ;

Maddox, T ;

Gong, XQ ;

Tang, DL ;

Coffee, M ;

Ding, I .

RADIATION RESEARCH, 1998, 150 (02) :204-211

← 1 2 →